Advancing KNX100 for the treatment of opioid withdrawal: preclinical efficacy and toxicology, and a phase 1 clinical program
Ended Cooperative Agreement Awarded Last action
- Award ID
- UG3DA048743
- Recipient
-
Kinoxis Therapeutics PTY LTD UEI GSKYRUM72Q53
- Awarding agency
-
National Institute on Drug Abuse
National Institutes of Health, Department of Health and Human Services
- Obligated
- $2,792,900
Award facts
- Assistance listing
- 93.279 Drug Use and Addiction Research Programs
- Completion date
- Originally
- Place of performance
- Australia
Award details come from USAspending.gov.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | -$6,040 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Original award | $2,798,940 |
Quick answers
Who received award UG3DA048743?
UG3DA048743 was awarded to Kinoxis Therapeutics PTY LTD by National Institute on Drug Abuse (National Institutes of Health) on September 30, 2019.
How much is award UG3DA048743 worth?
$2,792,900 has been obligated on UG3DA048743.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award